731 related articles for article (PubMed ID: 23312463)
1. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
Heng DY; Xie W; Regan MM; Harshman LC; Bjarnason GA; Vaishampayan UN; Mackenzie M; Wood L; Donskov F; Tan MH; Rha SY; Agarwal N; Kollmannsberger C; Rini BI; Choueiri TK
Lancet Oncol; 2013 Feb; 14(2):141-8. PubMed ID: 23312463
[TBL] [Abstract][Full Text] [Related]
2. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma: Model development and external validation with Memorial Sloan Kettering Cancer Center model and the international metastatic renal cell carcinoma database consortium model.
Shin D; Jeong CW; Song C; Kang M; Seo SI; Kim JK; Lee H; Chung J; Hong SH; Hwang EC; Kwak C; Park JY
Medicine (Baltimore); 2021 Aug; 100(31):e26826. PubMed ID: 34397846
[TBL] [Abstract][Full Text] [Related]
4. Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry.
Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
Cancer Res Treat; 2019 Apr; 51(2):758-768. PubMed ID: 30189720
[TBL] [Abstract][Full Text] [Related]
5. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
6. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.
Chrom P; Zolnierek J; Bodnar L; Stec R; Szczylik C
Int J Clin Oncol; 2019 May; 24(5):526-532. PubMed ID: 30604160
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma.
Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Hamano I; Fujita N; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
Int J Urol; 2019 Oct; 26(10):992-998. PubMed ID: 31342557
[TBL] [Abstract][Full Text] [Related]
8. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort.
Tamura K; Osawa T; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Sugimoto M; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Komiyama M; Tanaka K; Yokomizo A; Kohei N; Shinohara N; Miyake H;
Jpn J Clin Oncol; 2021 Apr; 51(5):810-818. PubMed ID: 33479762
[TBL] [Abstract][Full Text] [Related]
9. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
Tamura K; Ando R; Takahara K; Ito T; Kanao K; Yasui T; Shiroki R; Miyake H
Urol Oncol; 2021 Jan; 39(1):78.e1-78.e8. PubMed ID: 32958444
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
Kubackova K; Melichar B; Bortlicek Z; Pavlik T; Poprach A; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Prausova J; Buchler T;
Target Oncol; 2015 Dec; 10(4):557-63. PubMed ID: 25903462
[TBL] [Abstract][Full Text] [Related]
11. A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation.
Derosa L; Bayar MA; Albiges L; Le Teuff G; Escudier B
Angiogenesis; 2019 Aug; 22(3):383-395. PubMed ID: 30739258
[TBL] [Abstract][Full Text] [Related]
12. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.
Harshman LC; Xie W; Bjarnason GA; Knox JJ; MacKenzie M; Wood L; Srinivas S; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger C; North S; Rini BI; Heng DY; Choueiri TK
Lancet Oncol; 2012 Sep; 13(9):927-35. PubMed ID: 22877847
[TBL] [Abstract][Full Text] [Related]
13. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models.
Westerman ME; Shapiro DD; Tannir NM; Campbell MT; Matin SF; Karam JA; Wood CG
BJU Int; 2020 Dec; 126(6):745-753. PubMed ID: 32623821
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Heng DY; Xie W; Regan MM; Warren MA; Golshayan AR; Sahi C; Eigl BJ; Ruether JD; Cheng T; North S; Venner P; Knox JJ; Chi KN; Kollmannsberger C; McDermott DF; Oh WK; Atkins MB; Bukowski RM; Rini BI; Choueiri TK
J Clin Oncol; 2009 Dec; 27(34):5794-9. PubMed ID: 19826129
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.
Bukowski RM; Negrier S; Elson P
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6310S-4S. PubMed ID: 15448023
[TBL] [Abstract][Full Text] [Related]
16. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
[TBL] [Abstract][Full Text] [Related]
17. Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.
de Bruijn RE; Nijkamp J; Noe A; Horenblas S; Haanen JB; Prevoo W; Bex A
Urol Oncol; 2016 Jun; 34(6):258.e7-258.e13. PubMed ID: 26822077
[TBL] [Abstract][Full Text] [Related]
18. Baseline Edmonton Symptom Assessment System and survival in metastatic renal cell carcinoma.
Graham J; Gingerich J; Lambert P; Alamri A; Czaykowski P
Curr Oncol; 2018 Aug; 25(4):e319-e323. PubMed ID: 30111978
[TBL] [Abstract][Full Text] [Related]
19. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy.
Tamura K; Matsushita Y; Watanabe H; Motoyama D; Ito T; Sugiyama T; Otsuka A; Miyake H
Urol Oncol; 2020 Jan; 38(1):6.e9-6.e16. PubMed ID: 31400935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
